CanniMed Therapeutics Inc. announced that it has entered into a global marketing and distribution agreement with Fagron NV of Rotterdam. Under the Agreement, Fagron and CanniMed will work closely together in utilizing Fagron’s extensive infrastructure to supply CanniMed’s medicinal cannabis products in Germany and other specified countries. Pursuant to the terms of the Agreement, CanniMed is working to supplement its Canadian GMP compliant status with GMP certification in Europe for its cannabis products, which it anticipates will be achieved in second quarter of 2018. Fagron and CanniMed anticipate first product sales into Germany will commence in third quarter of 2018, subject to obtaining required export permits. Pursuant to the Agreement, CanniMed is Fagron’s supplier of cannabis products in the specified countries and the two companies will commit resources to develop and execute a combined marketing and distribution strategy to establish CanniMed as a strong brand in these countries.